Home Blog Page 814

KuCoin Reveals Tomorrowland Limited-Edition KuCard Ahead of Tomorrowland Winter

By
Advertorial Desk
-

Festival-inspired Visa card design debuts at Tomorrowland Winter, with an early-access waitlist available at the KuCoin Base Point

PROVIDENCIALES, Turks and Caicos Islands, March 20, 2026 /PRNewswire/ — KuCoin, a leading global crypto platform built on trust, today announced the Tomorrowland Limited-Edition KuCard, a special collaborative virtual payment card created under KuCoin’s partnership with Tomorrowland. The limited-edition Visa card introduces a festival-inspired design that reflects Tomorrowland’s immersive visual universe and will be revealed during Tomorrowland Winter 2026 in Alpe d’Huez, France.

The Tomorrowland Limited-Edition KuCard integrates KuCoin’s digital payment ecosystem with visual elements inspired by Tomorrowland’s signature artistic themes. The card design features luminous green particle motifs that echo the festival’s aesthetics of light, motion, and futuristic storytelling.

Soon to be issued on the Visa network, KuCard is designed to enable crypto-backed payments across millions of merchants where Visa is accepted once available. The limited-edition Tomorrowland virtual card will be released at a later stage and in limited quantities.

BC Wong, CEO of KuCoin, said:

“Tomorrowland brings together a global community around creativity, music, and shared experiences. Introducing the Tomorrowland Limited-Edition KuCard in this environment reflects how digital finance can connect with culture in meaningful ways. Through this collaboration, we hope to explore how crypto-enabled payments can gradually integrate into everyday experiences, while giving early supporters of the KuCard ecosystem an opportunity to engage with the concept at an early stage.”

The Tomorrowland Limited-Edition KuCard will be presented on-site during Tomorrowland Winter 2026, which takes place from March 21–28 in Alpe d’Huez and welcomes a global audience of electronic music fans, with around 24,000 visitors attending each day.

Festivalgoers will be able to visit the KuCoin Base Point in the Main Festival Area to view the card design and sign up for the early-access waitlist. Participants who join the waitlist will receive updates and priority access ahead of the card’s public availability. The on-site activation forms part of KuCoin’s broader festival presence themed “Guided into the Future,” connecting digital technology, culture, and future payment experiences within the Tomorrowland environment.

About KuCoin

Founded in 2017, KuCoin is a leading global crypto platform trusted by over 40 million users across 200+ countries and regions. The platform delivers innovative digital-asset services, offering access to 1,000+ listed tokens, spot and futures trading, institutional wealth management, and a Web3 wallet.

Recognized by Forbes and Hurun, KuCoin holds SOC 2 Type II and ISO 27001:2022 certifications, underscoring its commitment to top-tier security. KuCoin continues expanding its regulated footprint under CEO BC Wong, building a reliable and trusted digital-asset ecosystem.

Learn more: www.kucoin.com

Manulife Named “Asia’s Best Insurance Provider for Wealth Management” by Euromoney

By
Advertorial Desk
-

HONG KONG, March 20, 2026 /PRNewswire/ — Manulife today announced it has been named “Asia’s Best Insurance Provider for Wealth Management” at the 2026 Euromoney Private Banking Awards. The award recognizes Manulife’s excellence in delivering tailored and innovative wealth and legacy planning solutions to High-Net-Worth (HNW) individuals and families across the region.

The win reflects the company’s strong growth momentum, innovative product suite, unmatched cross-border service capabilities, and deep relationships with its distribution partners. It comes as demand for HNW wealth planning services continues to grow across the region. According to McKinsey analysis, an estimated US$5.8 trillion in assets is projected to transfer between generations across Asia-Pacific by 2030*, while regional financial wealth is expanding at approximately 9% CAGR through 2029#. This growth is being driven in part by a rising segment of global Asian citizens—internationally mobile families managing assets across multiple jurisdictions—who require cross-border insurance and legacy planning solutions at scale.

“We are honoured to be recognized by Euromoney as Asia’s leading life insurance provider for Wealth Management. This award reflects our continued commitment to meeting the unique needs of our HNW clients and partners. As intergenerational wealth transfer accelerates, we see a new generation of clients—today’s global Asian citizens—who prioritize flexibility, geographic diversification, and holistic solutions that combine wealth planning with health and longevity. Our strategy is built to meet these exact needs, leveraging our multi-hub platform and omni-channel distribution to deliver best-in-class solutions that help our clients protect their legacy and secure their future across borders and generations.”

— Bonnie Qiu, CEO, Global High-Net-Worth, Manulife

During the award assessment period, Manulife achieved high double-digit sales growth in business generated from private banks and international brokers serving HNW clients in Asia. Manulife’s success is underpinned by a comprehensive product proposition and policy structuring expertise, as well as strong underwriting capacity backed by its strong relationships with re-insurers.

In June 2025, Manulife was ranked first in the life insurance sector for artificial intelligence (AI) maturity in the inaugural Evident AI Index for Insurance, ranking in the top five across the insurance industry overall. Applied directly to its HNW business, Manulife has embedded generative AI into the HNW underwriting process, significantly reducing turnaround times for large and complex cases.

Manulife’s HNW strategy integrates its four hubs—Hong Kong, Singapore, Bermuda, and Dubai—to provide seamless multi-jurisdictional access and specialist local execution for globally mobile families.

“As HNW clients’ needs in Hong Kong become increasingly sophisticated, our role has evolved beyond product provision. As a leading international financial centre, Hong Kong continues to attract HNW families with complex wealth and legacy planning needs. By bringing together our diversified distribution model, bespoke innovative solutions, and strong underwriting capabilities—supported by our Private Client Wealth Planning team—we are able to provide integrated guidance on complex matters such as trust and legacy structuring. We are uniquely positioned to help globally mobile families protect and grow their wealth across generations.”

— Patrick Graham, CEO, Manulife Hong Kong & Macau

The business also saw strong momentum in Singapore, another key pillar of its regional HNW strategy.

“Singapore’s reputation as a secure and stable wealth hub continues to attract HNW families with increasingly complex needs, and they require an insurer with proven capabilities. Our recent issuance of a landmark US$300 million policy demonstrates the market’s confidence in our financial strength and deep technical expertise. It underscores our ability to structure and underwrite large, sophisticated cases, while helping high net worth families address their wealth and legacy priorities with tailored, well structured solutions.”

— Benoit Meslet, CEO, Manulife Singapore

Looking ahead, Manulife plans to continue its investment in the HNW segment by expanding its service capabilities across the region, driving ongoing product innovation with a focus on flexibility and liquidity, and further building out its health and longevity ecosystem.

About Manulife

Manulife Financial Corporation is a leading international financial services provider, headquartered in Toronto, Canada. Anchored in our ambition to be the number one choice for customers, we operate as Manulife across Canada and Asia, and primarily as John Hancock in the United States, providing financial advice, insurance and health solutions for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment solutions, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2025, we had more than 37,000 employees, over 106,000 agents, and thousands of distribution partners, serving over 37 million customers with operations across 25 markets globally. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges, and under ‘945’ in Hong Kong. Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.

* https://www.mckinsey.com/industries/financial-services/our-insights/asia-pacifics-family-office-boom-opportunity-knocks

# https://www.bcg.com/press/24june2025-organic-growth-advantage-financial-wealth-hits-record-high#:~:text=Asia%2DPacific%20is%20poised%20to,reaching%20%2414.4%20trillion%20in%202024

Everything You Need to Know Before You Start Trading Gold – The Complete JustMarkets Review

By
Advertorial Desk
-

HO CHI MINH CITY, Vietnam, March 20, 2026 /PRNewswire/ — As 2026 unfolds, gold continues to show the same resilient behavior that has long made it a preferred asset during uncertain economic cycles. While short-term fluctuations are common, the metal has generally held its ground amid shifting interest-rate expectations and geopolitical concerns.


For beginners, this mix of stability and volatility can be both appealing and confusing. Understanding what affects gold prices and what tools you need to navigate the market is essential before placing your first trade.

Understanding the Basics of Gold Trading

Gold trading isn’t simply about predicting whether the price will rise or fall. Traders need to grasp how macroeconomic data, inflation trends, currency movements, and global events influence the metal.

A common takeaway from a JustMarkets review is that new traders often overlook the importance of studying these external factors. Gold tends to react strongly to interest-rate decisions, particularly from the U.S. Federal Reserve, and to shifts in the U.S. dollar. Beginners should learn to follow these indicators before they begin making decisions with real money.

 Another point worth noting is the range of ways you can trade gold. Some prefer spot trading or CFDs for short-term strategies, while others lean toward longer-term approaches. Each method has its own risk profile, so clarifying your goals, whether hedging, speculating, or diversifying, is a step that shouldn’t be skipped.

Choosing the Right Environment for Trading

Before stepping into the market, traders need a stable trading environment. This includes a secure platform, access to educational resources, and tools that are easy to navigate.

According to insights often highlighted in a JustMarkets review, beginners tend to benefit from platforms that allow them to start with a small budget and gradually scale up their exposure. These elements don’t guarantee success, but they do help reduce early mistakes by making it easier to analyze the market and manage risk.

A user-friendly interface also matters more than many realize. When you’re new to trading, identifying trends, placing orders, or adjusting stop-loss levels should feel straightforward rather than intimidating. Even a small delay or a confusing layout can influence decision-making, especially in a fast-moving gold market.

Risk Management and Emotional Control

Even though gold is often viewed as a “safe-haven,” trading it still involves significant risk. Beginners should create a clear plan: how much they can afford to risk, when to exit a trade, and how to avoid emotional decisions.

Based on observations commonly mentioned in a JustMarkets review, new traders tend to underestimate how quickly gold can move during major news events. Using risk-management tools (such as stop-loss orders) provides essential protection, especially when starting out.

It’s also important to track your performance through a trading journal. Documenting each trade forces you to reflect on your strategy, recognize recurring mistakes, and refine your approach over time.

Final Thoughts

Trading gold in 2026 offers opportunity, but only if approached with preparation and realistic expectations. A basic understanding of market drivers, access to reliable tools, and a disciplined mindset can make the learning curve far smoother. With patience and consistent study, beginners can navigate the gold market with greater confidence and clarity.

China’s 2026 Government Work Report Indicates a New Cycle of Quality Enhancement for Commercial Real Estate Stock

By
Advertorial Desk
-

Cushman & Wakefield Interpretation Report Highlights Eight Impact Areas for Real Estate Market


HONG KONG SAR – Media OutReach Newswire – 20 March 2026 – Global real estate services firm Cushman & Wakefield has released its China’s Two Sessions 2026: Interpreting the Government Work Report publication. Against a backdrop of increasingly complex domestic and international conditions, the 2026 government work report outlines more flexible and adaptive targets for national economic development. These policy directions will have a profound influence on the real estate sector. The market’s transition from focusing on incremental expansion to revitalizing and optimizing existing assets — combined with the accelerating integration of artificial intelligence across industries —will reshape market structures, redefine asset values, and reconfigure spatial development patterns in far-reaching ways.

Macroeconomic Stability Strengthens the Foundation for Commercial Real Estate Stabilization

China’s core economic targets for 2026 are clearly defined, with GDP growth set between 4.5%–5%, balancing the dual objectives of stabilizing growth and adjusting structure. This forms a strong macro foundation for the stabilization and gradual recovery of the commercial real estate sector. Between 2024 and 2025, GDP growth remained steady at around 5.0%. For 2026, the fiscal deficit ratio is maintained at a relatively high 4.0%, with RMB4.4 trillion in local special‑purpose bonds. The quota for ultra‑long‑term special treasury bonds is further expanded to RMB1.3 trillion. Coordinated fiscal and monetary policies will continue to support leasing demand recovery and improved business sentiment in the commercial property market.

Accelerated Industry Transformation Sees Quality Enhancement of Existing Assets Become the Core Theme

The report emphasizes a three‑pronged approach of “city‑specific policies to control new supply, reduce inventory, and improve quality”, while encouraging diverse channels to revitalize existing housing stock and advancing the construction of “good homes.” This marks an accelerated shift from incremental expansion to quality enhancement of existing assets. In 2024, China’s real estate value‑added as a proportion of GDP was just 6.3%, far below the 12.56% average of developed economies. This reflects a structural imbalance characterized by heavy investment in development and insufficient focus on services and leasing. The ongoing transition will make asset management, property services, and leasing operations increasingly central to asset valuation.

Consumption‑Driven Momentum Creates a New Growth Window for Retail Properties

Consumption‑boosting policies are injecting new vitality into the retail property market. The government work report allocates RMB250 billion of ultra‑long‑term special treasury bonds to support product upgrades and replacement, complemented by RMB100 billion in coordinated fiscal‑financial funds — creating a RMB350 billion consumption stimulus package. In 2025, China’s total retail sales of consumer goods exceeded RMB50 trillion, with per‑capita GDP reaching USD13,953, signaling a critical inflection point where service‑oriented consumption accelerates. With services currently accounting for just 46.1% of consumption, there remains significant room for growth. Policies promoting “high‑quality service consumption” and “new consumption scenarios,” combined with the promotion of staggered school holidays in spring and autumn, will create opportunities for high‑quality shopping centers focused on experiential and social retail formats.

AI‑Powered Intelligent Economy Drives an Upgrade in Office Market Demand

The rapid evolution of the intelligent economy is reshaping office market demand. The work report calls for expansion of “AI+,” wider deployment of intelligent agents, and accelerated development of large‑scale computing clusters, indicating the transition of AI into commercialized and scaled applications. In 2025, China’s core digital economy industries accounted for more than 10.5% of GDP, with the target set at 12.5% during the 15th Five‑Year Plan. AI‑related companies are expected to become key new leasing drivers in 2026. This will also stimulate a fresh investment cycle for data centers and industrial parks, with core computing hub cities — in the Beijing‑Tianjin‑Hebei region, Yangtze River Delta, and the Guangdong‑Hong Kong‑Macao Greater Bay Area — set to benefit first.

Capital Market Reforms Expand, Enabling a Full “Investment–Financing–Management–Exit” Cycle for Commercial Real Estate

Capital market reforms continue to support expansion in commercial real estate investment. The work report calls for deepened reform of comprehensive investment and financing mechanisms, expanded exit channels for private equity and venture capital, and accelerated growth of the public REITs market. By 2025, China’s public REITs issuance exceeded RMB210 billion, making it the largest REITs market in Asia. In 2026, commercial public REITs enter their first year of development, with pilots extended to hotels and commercial offices. This establishes a “dual‑engine” landscape of “infrastructure + commercial real estate” and enables a more complete investment‑financing‑management‑exit cycle

Further Opening‑Up Boosts Cross‑Border Logistics and Foreign Investment Demand

China’s opening‑up objectives in 2026 feature two core characteristics: expanding services sector openness to attract foreign investment, and promoting standardized, high‑quality development of cross‑border e‑commerce. In 2025, China’s cross‑border e‑commerce imports and exports totaled RMB2.75 trillion, with growth outpacing overall trade for the fourth consecutive year. The sector’s demand for high‑specification warehouses — characterized by high density and rapid turnover —continues to rise. Cushman & Wakefield data shows that the warehouse market is experiencing volume growth alongside price adjustment, with notable regional differences. As cross‑border e‑commerce becomes more regulated, and cold‑chain logistics demand continues to expand, green‑certified, intelligent high‑spec warehouses are expected to gain a competitive advantage.

Advancement of New Urbanization Brings Opportunities for Urban Clusters and Urban Renewal

A notable highlight among 2026 urbanization policies is the first‑ever proposal to build “innovation‑driven industrial communities and business communities.” This concept breaks the traditional boundary between industrial parks and business districts, fostering integrated complexes that combine office, commercial, and residential functions. The report also supports the development of world‑class city clusters in the Beijing‑Tianjin‑Hebei region, the Yangtze River Delta, and the Greater Bay Area, while enhancing the dual‑city Chengdu‑Chongqing Economic Circle and accelerating growth in the middle‑Yangtze city cluster — further intensifying regional differentiation in the commercial property market. Urban renewal and revitalization of existing stock assets are core pillars of the current urbanization strategy. Policies promoting the reuse of existing land and idle buildings align closely with efforts to revitalize existing housing stock. For owners and operators of prime urban assets, regeneration projects offer strategic opportunities for repositioning and value enhancement.

Green Transformation Prompts Sustainability Certifications to Become a Key Competitive Advantage

The work report dedicates a standalone section to the green transition, announcing dual controls on total carbon emissions and intensity, as well as new policy tools such as zero‑carbon parks and a national low‑carbon transition fund. In 2025, China’s national carbon market saw 235 million tons of allowances traded, with transaction value reaching RMB14.63 billion, up approximately 24% year‑on‑year. Carbon costs have become an increasingly important factor in corporate leasing and location decisions. With 97.9% of newly built urban buildings in 2024 meeting green standards, green retrofits of existing buildings are gaining momentum. Commercial properties certified under LEED, WELL, and China’s Green Building Label standard enjoy notable advantages in rental premiums and tenant attraction.

Sabrina Wei, Chief Policy Analyst and Head of Research, North China, Cushman & Wakefield, said, “The 2026 government work report outlines a clear development vision for commercial real estate characterized by macroeconomic stability, targeted policies, and structural transformation. A GDP growth rate of 4.5%-5% will provide market stability, a RMB350 billion consumption stimulus will activate demand for retail properties, “AI+” will reshape the office market; capital market reforms and public REITs will enable a full “Investment–Financing–Management–Exit” cycle, urban renewal will unlock values of existing assets, and green certification will define new competitiveness for the industry. As the real estate industry transitions from a construction‑focused model to one centered on operations and services, institutions with strong capabilities in asset management and high‑quality operational service delivery will be best positioned to capture the emerging opportunities of this transformative new cycle.”

To access the full report please click here.
Hashtag: #CushmanWakefield

The issuer is solely responsible for the content of this announcement.

About Cushman & Wakefield

Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for occupiers and investors with approximately 53,000 employees in over 350 offices and nearly 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2025, the firm reported revenue of $10.3 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit or follow us on LinkedIn ().

Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability

By
Advertorial Desk
-

SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress.

Dr. Jay Mei, Antengene’s Founder, Chairman, and CEO, commented, “Over 2025 and prior years, Antengene has built a solid foundation for long-term growth, including a robust late-stage clinical pipeline, the proprietary AnTenGager™ T-cell engager (TCE) platform, and the commercialization of XPOVIO®, which is generating revenue across 10 APAC markets. As we enter into 2026, we are beginning to translate this foundation into tangible value creation. Our recent global licensing agreement with UCB for ATG-201 (CD19×CD3 TCE) represents the first out-licensing transaction for the company and the AnTenGager™ platform, validating its global competitiveness and marks a clear inflection point for Antengene. Antengene will receive USD 80 million (comprised of an initial upfront payment of USD 60 million and additional near-term milestone payments of USD 20 million), and is eligible to receive more than USD 1.1 billion in success-based development, regulatory and sales milestones, along with tiered royalties on future net sales.

At the same time, our late-stage clinical programs continue to advance. ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) has demonstrated strong efficacy and best-in-class safety in gastric cancer and other CLDN18.2+ solid tumors, with frontline combination studies in gastric cancer underway, positioning upcoming data as a potential key value inflection point. The company plans to initiate a pivotal Phase III monotherapy trial in gastric cancer in 2026, with enrollment starting in the second half of 2026. ATG-037 (oral CD73 small molecule inhibitor) has shown encouraging efficacy in checkpoint inhibitor (CPI) resistant tumors in combination with anti-PD-1 therapy and is well positioned for combination use with next-generation CPIs such as PD-1×VEGF bispecific antibodies. Together, these programs represent important future value drivers as they approach key clinical milestones. In parallel, the AnTenGager™ TCE platform will remain open for global collaboration, enabling continued licensing and partnership opportunities. These collaborations represent a new and important revenue stream for the company, with the potential to generate multiple revenue streams through upfront payments, development and regulatory milestones, and potential royalties.

Looking ahead, we will continue to advance our clinical pipeline with disciplined cost control while expanding our innovation capabilities across new and emerging scientific platforms. With multiple novel modalities in development, we believe we are well positioned to further strengthen our R&D engine and support sustainable long-term growth.”

【Business Updates】

1.   AnTenGager™ TCE Platform

  • TCE platform with steric hindrance masking technology: AnTenGager™ is Antengene’s proprietary, second-generation TCE platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune diseases, solid tumors and hematological malignancies indications. Leveraging this platform, Antengene has discovered multiple investigational programs:
    • ATG-201 (CD19 x CD3 TCE): ATG-201 is a novel “2+1” CD19-targeted T-cell engager developed on the AnTenGager™ TCE platform for the treatment of B cell related autoimmune diseases. Antengene has entered into a global license agreement with UCB for ATG-201. The company plans to submit the IND application for ATG-201 in the first quarter of 2026, and will transfer subsequent clinical development to UCB upon the completion of the first-in-human (Phase I) clinical trial. In return of the license rights granted to UCB, Antengene will receive an upfront and near term milestone payment of USD 80 million (comprised of an initial upfront payment of USD 60 million and additional near-term milestone payments of USD 20 million upon satisfaction of certain conditions) and would be eligible to receive future success-based development and commercial milestone payments of over USD 1.1 billion, as well as tiered royalties on future net sales.
    • ATG-106 (CDH6 x CD3 TCE): A global first-in-class CDH6 x CD3 targeted TCE being developed for the treatment of ovarian cancer and kidney cancer. The Company plans to submit an IND application for ATG-106 in the second quarter of 2027.
    • ATG-112 (ALPPL2 x CD3 TCE): A global first-in-class ALPPL2 x CD3 targeted TCE being developed for the treatment of gynecological tumors, digestive system malignancies, bladder cancer and NSCLC. The Company plans to submit an IND application for ATG-112 in the second quarter of 2027.
    • Additional TCE programs for solid tumors: Antengene plans to submit an IND application for ATG-110 (LY6G6D × CD3 TCE) in the first half of 2027 for the treatment of microsatellite-stable colorectal cancer. In addition, ATG-115 (an undisclosed bispecific antibody) and two undisclosed trispecific antibody programs are currently in preclinical development.

2.   Key Clinical Programs

  • ATG-022 (CLDN18.2 Antibody-Drug Conjugate)
    • Data from the Phase II CLINCH study: ATG-022 has demonstrated potent anti-tumor activity across all levels of CLDN18.2 expression and maintained a favorable safety profile, with the incidence of Grade 3 or higher treatment-related adverse events (TRAEs) standing at only 19.4%, suggesting promising potential for frontline combination therapy. Meanwhile, ATG-022 has also shown positive efficacy in patients with non-gastrointestinal tumors, and the Company expects further expansion of its therapeutic indications to treatable patient populations beyond gastrointestinal cancers (for detailed data, please refer to the Company’s press release issued in January 2026 at https://www.antengene.com/newsinfo/459). The Company expects to release the latest clinical data of ATG-022 in the second quarter of 2026.
    • Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase II CLINCH study and the Phase Ib/II CLINCH-2 study of ATG-022 in Mainland of China and Australia. The Company continues to advance the clinical development of ATG-022 across different lines of gastric cancer treatment, including first-line therapy in combination with checkpoint inhibitors (CPIs) and chemotherapy (CAPOX/FOLFOX); second-line therapy in combination with CPIs; and third-line therapy as monotherapy, covering patients with varying levels of CLDN18.2 expression. In addition, the CLINCH study of ATG-022 includes a basket trial cohort evaluating multiple tumor types, with the majority of patients continuing to receive treatment.
  • ATG-037 (Oral CD73 Small Molecule Inhibitor)
    • Data from the Phase Ib/II STAMINA study: Following the initiation of a global clinical collaboration with MSD, Antengene is evaluating ATG-037 in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with checkpoint inhibitor (CPI)-resistant melanoma and non-small cell lung cancer (NSCLC). These findings suggest that ATG-037 has clinically meaningful therapeutic potential in multiple tumor types, particularly in patients who are CPI-resistant (for detailed data, please refer to the Company’s press release issued in November 2025 at https://www.antengene.com/newsinfo/452). The Company expects to release the latest clinical data of ATG-037 in the fourth quarter of 2026.
    • Clinical development pathways: existing data show that ATG-037 holds enormous therapeutic potential for the treatment of first-line or CPI-resistant melanoma, with promising potential for expansion into other tumor types. Antengene’s clinical development roadmap for ATG-037 has four main components: 1. combination with CPI for the treatment of CPI-resistant unresectable and metastatic melanoma (second-line treatment); 2. combination with CPI for the first-line treatment of unresectable or metastatic melanoma; 3. combination with CPI for the treatment of CPI-resistant unresectable or metastatic NSCLC (second-line treatment); 4. active expansion into other CPI-resistant tumor types supported by the encouraging proof-of-concept data; 5. explore potential combinations with next-generation CPIs such as PD-1×VEGF bispecific antibody.
    • Combination with PD-1/VEGF Bispecific Antibody: Antengene has entered into a clinical collaboration agreement with Junshi Biosciences to evaluate the synergistic therapeutic potential of Antengene’s ATG-037 in combination with Junshi Biosciences’ JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland of China. The combination therapy of ATG-037 and JS207 may constitute a potential “triple-axis” strategy. With the potential to deepen responses while maintaining a favorable safety profile, the combination of ATG-037 with JS207 may further improve the durability of benefit and may translate into improved overall survival (OS).

3.   Next Generation ADCs and  Other Novel Programs 

  • ATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an “IO + ADC” dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of IO therapies. By simultaneously blocking B7-H3- and PD-L1-mediated immunosuppressive signaling, ATG-125 effectively activates T cells and induces immunological memory. Preclinical studies demonstrate that the bispecific ADC delivers superior in vivo efficacy compared with single-target B7-H3-ADC or PD-L1-ADC approaches. The Company plans to submit an IND application for ATG-125 in the second quarter of 2027.
  • ATG-207 (αCD3-TGF-β Bispecific Fusion Protein): ATG-207 is a globally first-in-class αCD3-TGF-β bispecific fusion protein being developed for the treatment of T cell–mediated autoimmune diseases. The Company plans to present preclinical data for ATG-207 for the first time at an international scientific conference in 2026.

4.   Commercialized Product

  • Mainland of China: In July 2025, XPOVIO® received approval for its third indication in the Mainland of China, bringing a new treatment option to patients with multiple myeloma (MM) who have received at least one prior therapy. Among the three approved indications of XPOVIO®, two have already been included in China’s National Reimbursement Drug List (NRDL), including XPOVIO® monotherapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and XPOVIO® in combination with dexamethasone for the treatment of R/R MM.
  • Taiwan Market: In February 2025, XPOVIO® received national reimbursement approval in Taiwan market, making it the fifth APAC market to secure reimbursement coverage after mainland of China, South Korea, Australia, and Singapore.
  • Hong Kong, China：In December 2025, XPOVIO® received approval for two additional indications in Hong Kong, China for the treatment of MM and R/R DLBCL.
  • South Korea: In March 2026, XPOVIO® received national reimbursement approval for its second indication in South Korea for the treatment of MM.
  • ASEAN Markets: In March 2025, XPOVIO® was approved in Indonesia. To date, XPOVIO® has been approved for multiple indications in ten countries and regions across the APAC region. In December 2025, XPOVIO® received approval for its third indication in Malaysia for the treatment of DLBCL.

【Highlights of Financial Results】

1. Strong Cash Reserves Securing the Execution of Long-Term Strategies
As of the end of the reporting period, the company held RMB 734 million in cash and bank balances, which is sufficient to support existing key programs to the proof-of-clinical-concept stage, securing the execution of the company’s long-term strategies. Antengene will receive USD 80 million (comprised of an initial upfront payment of USD 60 million and additional near-term milestone payments of USD 20 million), and is eligible to receive more than USD 1.1 billion in success-based development, regulatory and sales milestones, along with tiered royalties on future net sales, providing strong momentum for our future R&D and sustainable growth.

To learn more about the 2025 full-year results, please see the full announcement in the “Investor Relations” section on the company’s website.

About Antengene 
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), and ATG-125 (B7-H3 × PD-L1 bispecific ADC).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com 

PCHi 2026: World’s Largest Cosmetics Ingredients Exhibition Opens in Hangzhou

By
Advertorial Desk
-
  • 860+ exhibitors from 26 countries and regions across 70,000 sqm
  • Close to 50 new product launches, including global and China debuts
  • 295 product submissions and 19 engineer nominations for the Fountain Awards
  • Technical program covering formulation, regulation, and emerging technologies

HANGZHOU, China, March 20, 2026 /PRNewswire/ — The Personal Care and Homecare Ingredients (PCHi) trade show, organized by Reed Sinopharm Exhibitions, is underway at the Hangzhou Grand Convention & Exhibition Center, bringing together more than 860 exhibitors from 26 countries and regions across 70,000 square meters. As the world’s largest cosmetics ingredients exhibition and the first major industry event of the year, PCHi 2026 reinforces its role as a global platform connecting ingredient suppliers with brands, formulators, and manufacturers seeking to shape product pipelines for the year ahead.

The three-day event convenes industry professionals at a critical point in the industry calendar, when sourcing strategies and innovation priorities are actively being defined. With China continuing to play a central role in global beauty consumption and production, PCHi provides international participants with direct access to one of the most influential markets for ingredient innovation and application.

Opening day saw the unveiling of close to 50 new product launches, with exhibitors presenting developments across ingredient technologies, biotechnology, formulation systems, testing services, packaging materials, and AI-enabled applications — reflecting strong momentum in performance-driven, sustainable, and compliance-ready solutions.

Visitors noted the value of engaging directly with suppliers while evaluating a broad cross-section of technologies in one setting, enabling efficient benchmarking and more informed sourcing decisions.

“China’s personal care market continues to influence how and where innovation is developed and applied,” said a spokesperson from Reed Sinopharm Exhibitions (RSE). “PCHi brings the global industry together at scale — offering a platform to launch new technologies, evaluate opportunities, and align strategies for the year ahead.”

Alongside the exhibition, technical seminars and forums across the three days will cover more than 20 topics, including formulation science, regulatory developments, dermo-cosmetics, and cosmetics efficacy testing. Dedicated feature areas — including the Innovation Zone, New Products Showcase, New Technology Sessions, and Sustainability Zone — highlight emerging technologies and product concepts.

The PCHi Fountain Awards winners were announced on the opening day of the exhibition, with 33 products and three engineers recognized. The Awards serve as a reference point for excellence within the industry, highlighting notable achievements while supporting continued progress in innovation and product development.

The next edition of PCHi will take place from 24–26 February 2027 in Guangzhou, continuing its role as a key meeting point for the global cosmetics ingredients industry.

For more information, visit www.pchi-china.com/en.

Global Buyers Convene in the Lighting Capital for Efficient Deals and Business Opportunities; Global Buyer Spring Sourcing Fair Paves a “Fast Track” for Cross-Border Procurement

By
Advertorial Desk
-

ZHONGSHAN, China, March 20, 2026 /PRNewswire/ — On the third day of the 34th Guzhen Lighting Fair, the exhibition hall was bustling with activity. Buyers and exhibitors from around the globe engaged in enthusiastic exchanges, while the sounds of inquiries and negotiations echoed throughout the venue, creating a lively and dynamic atmosphere.

The “Global Buyers Spring Sourcing”, a highlight of this exhibition, has successfully concluded. More than 100 influential overseas buyers gathered to participate in two core sessions: the “Denggle.com Business Matching” and the ” Interstellar Plaza Sourcing Tour.” This event created a trade platform that seamlessly integrates precise matchmaking, in-depth communication, and on-site visits for both suppliers and buyers.

01 Denggle.com Business Matching: Precise alignment of supply and demand for mutual cooperation and success

This year’s Global Buyers Spring Sourcing successfully hosted three Online Lighting Business Matching, where hundreds of overseas buyers engaged in precise and efficient communication with carefully selected premium exhibitors. The event was packed, and the negotiation atmosphere was lively.

At this session of Lighting Fair, the business matching for the Malaysian buyer group served as a vital bridge for precisely connecting with overseas resources and facilitating China-Malaysia lighting trade cooperation. It brought together influential buyers from fields such as retail distribution, real estate, architectural design, civil engineering, electrical engineering, and lighting wholesale. To ensure efficient negotiations, Guzhen Lighting Fair pre-matched each buyer with the most suitable exhibitors based on the specific procurement lists submitted prior to the event. Both parties engaged in in-depth discussions regarding purchase needs, product details, and cooperation models, leading to precise and effective on-site communication.

The other two business matching events were equally remarkable with target on the key buyers from Russia, Southeast Asia, West Asia, Europe, Africa, and South America. These meetings continued the efficient service model of “precise pre-event matching”, allowing suppliers and buyers to effectively connect through one-on-one negotiations. Due to the smooth communication, many exhibitors secured purchase intentions.

02 Interstellar Plaza Sourcing Tour: In-depth exploration of the source market for on-site product selection

In addition to the business matching at the main venue, the Global Buyers Spring Sourcing also organized the Interstellar Plaza Sourcing Tour. This event invited the Malaysian buyer group to experience the distinctive “Exhibition- Megastore Linkage” model, enabling them to gain a deeper understanding of Guzhen’s lighting industry chain through a combination of open negotiations and on-site visits.

During the event, a representative from Interstellar Plaza delivered a speech, providing a detailed introduction to the diverse lighting brands, innovative designs, and comprehensive supporting services available at the plaza, highlighting Guzhen’s strong supply chain advantages as a leading hub for lighting production. Subsequently, a buyer representative shared insights into the current consumer trends and specific demands of the Malaysian lighting market, offering valuable overseas market forecast to the merchants in attendance. Subsequently, a merchant representative spoke, warmly welcoming the overseas buyers and briefly introducing the product features and service advantages of their respective stores, providing additional information for the buyers’ store visits.

During the afternoon tea session, buyers and merchants gathered to discuss purchase needs and product features, establishing a robust foundation for the subsequent on-site visits. After the session, the buyer group, guided by staff, made on-site visits to several representative brand stores within the plaza. They gained an in-depth understanding of product craftsmanship and details and engaged in one-on-one discussions with merchants regarding purchase intentions. This provided overseas buyers with a more direct appreciation of the quality and strength of Guzhen manufacturing.

By combining precise matchmaking with on-site inspections, the Global Buyers Spring Sourcing has successfully facilitated mutual benefits for both suppliers and buyers, highlighting the effectiveness and value of the Guzhen Lighting Fair as a trade platform.

 

SCANOLOGY Introduces SIMSCAN-S Gen2, Palm-Sized 3D Scanner Delivering 0.015 mm Accuracy for High-Precision Inspection

By
Advertorial Desk
-

New handheld system helps manufacturers verify critical geometries, accelerate inspection workflows, and reduce costly rework.

HANGZHOU, China, March 20, 2026 /PRNewswire/ — Earlier this month, SCANOLOGY, a leading 3D scanning solution provider, announced the launch of the SIMSCAN-S Gen2, a new generation of palm-sized 3D scanner designed to help manufacturers perform high-precision inspections with greater confidence, speed, and flexibility.

Manufacturers are now required to verify micron-level accuracy while reducing inspection time and minimizing costly rework. The SIMSCAN-S Gen2 3D scanner addresses these challenges by combining metrology-grade accuracy, advanced geometric control, and high-speed data capture in a compact and fully wireless device.

High-Performance 3D Inspection

The SIMSCAN-S series is designed to meet these demanding inspection requirements. With dense, metrology-grade point clouds and accuracy up to 0.015 mm, the scanner captures detailed 3D data of holes, cylinders, and critical surfaces, providing a reliable foundation for complex dimensional analysis.

  • Fitting cylinders to holes to measure hole-to-hole distances
  • Extracting cross-sections to measure distances and radii
  • Comparing scan data with CAD models to generate deviation color maps
  • Conducting virtual assembly to evaluate gaps and overall fit

From Experience-Based to Data-Driven Quality Control

Unlike traditional inspection methods that rely on limited measurement points, SIMSCAN-S captures complete 3D surface data and compares it directly with CAD models.

The resulting color-map visualization clearly highlights even subtle deviations, allowing engineers to quickly identify potential issues in functional surfaces, machined features, and assembly-critical areas.

This shift toward data-driven inspection helps manufacturers improve traceability, reduce human error, and make faster quality decisions.

Compact, Wireless, and Built for Real-World Environments

Despite its powerful performance, the SIMSCAN-S Gen2 remains highly portable, featuring a 560 g magnesium-alloy body for easy handling during extended use.

Its fully wireless design, powered by edge computing and wireless data transmission, enables flexible scanning in confined, elevated, or complex environments without cables.

An integrated display provides real-time feedback to ensure data quality and efficient workflows.

Capture More Data, Faster

The SIMSCAN-S Gen2 delivers high-speed scanning performance with:

126 blue laser lines
Up to 8.1 million measurements per second
Frame rates up to 180 FPS

This enables engineers to capture large volumes of detailed 3D data quickly, even when scanning complex or intricate geometries.

As smart manufacturing continues to evolve, high-quality 3D data will play an increasingly important role in predictive maintenance, process optimization, and closed-loop quality control.

1...813814815...6,562Page 814 of 6,562